STOCK TITAN

Rise Nano Optics Ltd. Announces AGSM Results

(Very Positive)
Tags

Rise Nano Optics (CSE:EYE, OTCQB:RNOLF) reported that all resolutions were approved at its annual general and special meeting of shareholders held on August 5, 2026, at 10:00 a.m. Pacific Time. A total of 16,027,785 common shares, representing 39.35% of outstanding shares as of the record date, were represented.

Shareholders set the number of directors at five and elected all nominees. Four directors each received 16,027,785 votes for (100.00%). Director Nancy Goertzen received 1,137,048 votes for (7.09%) and 14,890,737 withheld (92.91%).

Shareholders also approved the appointment of Ziv Haft Certified Public Accountants (Israel), a BDO Member Firm, as auditors, the Company’s equity incentive plan, the continuation of the Company from the Business Corporations Act (British Columbia) to the Business Corporations Act (Ontario), and the repeal of all existing bylaws with the enactment of new By-Law No. 1. Each of these resolutions received 16,027,785 votes for (100%) and zero withheld.

Loading...
Loading translation...

Positive

  • AGSM participation 16,027,785 shares represented, equal to 39.35% of outstanding
  • All AGSM resolutions approved with 16,027,785 votes for and 0 withheld on key items
  • Equity incentive plan approved with 100% of votes cast (16,027,785 for)
  • Corporate continuation to Ontario approved with 16,027,785 votes for, 0 withheld
  • New By-Law No. 1 enacted, all prior bylaws repealed with unanimous votes cast

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) ("Rise" or the "Company"), is pleased to announce that all resolutions were passed at the annual general and special meeting of shareholders (the "AGSM") held yesterday in person at 10:00 am (Pacific Time).

Annual General and Special Meeting Results

A total of 16,027,785 common shares in the capital of the Company ("Common Shares") were represented at the AGSM, representing 39.35% of the votes attached to all outstanding Common Shares as at the record date. All of the matters submitted to the shareholders for approval as set out in the Company's notice of meeting and information circular (the "Circular") dated June 24, 2026, were approved.

Item 1. Number of Directors

The number of directors was set at five.

Votes For% of VotesVotes Withheld% of Votes
16,027,785100%00%

 

Item 2. Election of Directors

All director nominees listed in the Circular were elected as directors of the Company.

DirectorVote TypeNumber of VotesPercentage of Votes
Inas SaidFor
Withheld
16,027,785
-
100.00%
0.00%
Nabil JadounFor
Withheld
16,027,785
-
100.00%
0.00%
Ralf WiesmannFor
Withheld
16,027,785
-
100.00%
0.00%
John SinclairFor
Withheld
16,027,785
-
100.00%
0.00%
Nancy GoertzenFor
Withheld
1,137,048
14,890,737
7.09%
92.91%

 

Item 3. Appointment of Auditor

Ziv Haft Certified Public Accountants (Israel), a BDO Member Firm, were appointed as auditors of the Company.

Votes For% of VotesVotes Withheld% of Votes
16,027,785100%00%

 

Item 4. Approval of the Company's Equity Incentive Plan

Votes For% of VotesVotes Withheld% of Votes
16,027,785100%00%

 

Item 5. Approval of the Company's Continuation in Ontario

Approved the continuation of the Company's corporate existence from the Business Corporations Act (British Columbia) to the Business Corporations Act (Ontario).

Votes For% of VotesVotes Withheld% of Votes
16,027,785100%00%

 

Item 6. Approval of the Company's New Bylaws

Votes For% of VotesVotes Withheld% of Votes
16,027,785100%00%

 

Approved the repeal of all existing bylaws of the Company and the enactment of a new By-Law No. 1

About Rise

Rise is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented SpectraGuard technology integrates nanomaterial innovation, ophthalmic research, and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

For more information, visit: www.risenanooptics.com

Investor Contacts:
Danielle Shortall
Investor Relations
Email: Danielle.shortall@risenanooptics.com
Tel: +1 (437) 226 0612

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward‐Looking Statements

This news release contains forward-looking statements relating to the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the implementations of the Company's continuation in Ontario, the adoption and operation of the Company's new bylaws, the administration of the Company's equity incentive plan and the Company's future corporate governance, strategic initiatives financing activities and business objectives, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

Readers are cautioned that forward-looking information is not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the risk that the anticipated benefits of the Company's continuation into Ontario or adoption of new bylaws are not realized; the Company's ability to maintain compliance with applicable corporate, securities and stock exchange regulations; changes in market conditions; challenges in attracting and retaining qualified directors, officers, employees and consultants; and dilution resulting from the issuance of securities under the Company's equity incentive plan. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

 

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/308332

FAQ

What did Rise Nano Optics (RNOLF) shareholders approve at the August 2026 AGSM?

Shareholders approved all resolutions, including director elections, auditor appointment, equity incentive plan, corporate continuation to Ontario, and new bylaws. According to Rise Nano Optics, each non-director item received 16,027,785 votes for, representing 100% of votes cast and zero withheld.

How many Rise Nano Optics (RNOLF) shares were represented at the August 5, 2026 AGSM?

A total of 16,027,785 common shares were represented at the AGSM. According to Rise Nano Optics, this corresponded to 39.35% of the votes attached to all outstanding common shares as of the record date for the annual general and special meeting.

What was decided about the board of directors of Rise Nano Optics (RNOLF) at the 2026 AGSM?

Shareholders set the number of directors at five and elected all nominees. According to Rise Nano Optics, four directors received 16,027,785 votes for (100%), while nominee Nancy Goertzen received 1,137,048 votes for (7.09%) and 14,890,737 votes withheld (92.91%).

Which auditor did Rise Nano Optics (RNOLF) appoint at the August 2026 shareholder meeting?

Shareholders appointed Ziv Haft Certified Public Accountants (Israel), a BDO Member Firm, as auditor. According to Rise Nano Optics, this appointment was approved with 16,027,785 votes for and zero votes withheld, reflecting 100% support from the votes cast at the AGSM.

Did Rise Nano Optics (RNOLF) approve an equity incentive plan at its 2026 AGSM?

Yes, the company’s equity incentive plan was approved by shareholders at the AGSM. According to Rise Nano Optics, the resolution received 16,027,785 votes for and zero withheld, meaning 100% of the votes cast supported the equity incentive plan proposal.

What does the corporate continuation to Ontario mean for Rise Nano Optics (RNOLF) shareholders?

Shareholders approved continuing the company from British Columbia law to Ontario law. According to Rise Nano Optics, the continuation from the Business Corporations Act (British Columbia) to the Business Corporations Act (Ontario) passed with 16,027,785 votes for and no votes withheld.